• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 422395 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414689532 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414689532 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Stock Investors Bid Up Shares of Isis Pharmaceuticals, Up 2.1%

Published on Tue, 01/15/2013 - 13:17
By Peter Chu

One of today's stocks on the move is Isis Pharmaceuticals (NASDAQ:ISIS), up 2.1% to $13.98. The Dow Jones Industrial Average is now trading fractionally lower to 13,504 and the S&P is trading fractionally lower to 1,470.

Isis Pharmaceuticals (NASDAQ:ISIS) is currently priced 23.1% above its average consensus analyst price target of $10.75. The stock should find initial support at its 200-day moving average (MA) of $10.92 and further support at its 50-day MA of $9.68.

In the past 52 weeks, Isis Pharmaceuticals share prices have been bracketed by a low of $6.25 and a high of $15.61 and are now at $13.98, 124% above that low price. The 200-day and 50-day moving averages have moved 0.64% higher and 2.92% higher over the past week, respectively.

Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

DENTSPLY International (XRAY) Breaks Thr...

Shares of DENTSPLY International (NASDAQ:XRAY) have bullishly opened above the pivot of ...

Stock Investors Sell Off Shares of Stone...

Stone Energy (NYSE:SGY) is one of today's biggest movers, down 4.4% to $24.27. The S&P ...

Chart Industries Makes a Move: Down 4.5%...

Chart Industries (NASDAQ:GTLS) is one of today's notable stocks in decline, down 4.5% t ...

Next Resistance Level for Ameren (AEE) i...

Shares of Ameren (NYSE:AEE) have bullishly opened above the pivot of $41.38 today and h ...

Wisconsin Energy (WEC) Crosses Pivot Poi...

Shares of Wisconsin Energy (NYSE:WEC) have bullishly opened above the pivot of $48.35 t ...

Telecom Argentina Makes a Move: Up 4.5%...

Telecom Argentina (NYSE:TEO) is a company whose shares are active, trading 4.5% higher ...

Rosetta Resources Makes a Move: Down 4.6...

Rosetta Resources (NASDAQ:ROSE) is a company whose shares are active, trading 4.6% lowe ...

Dominion Resources (D) Approaches New Up...

Shares of Dominion Resources (NYSE:D) have bullishly opened above the pivot of $70.23 t ...